This result parallels recent clinical findings for patients with NSCLC treated with anti-PD-1 immunotherapy, in which a higher Ki-67 expression in circulating CD8+ T-cells was seen to predict superior durable clinical benefit and survival rate35,36. This evidence concerns the gene CD8A and non-small cell lung carcinoma.